[go: up one dir, main page]

MX2014006998A - Anticuerpo quimerico terapeutico anti-cd37 hh1. - Google Patents

Anticuerpo quimerico terapeutico anti-cd37 hh1.

Info

Publication number
MX2014006998A
MX2014006998A MX2014006998A MX2014006998A MX2014006998A MX 2014006998 A MX2014006998 A MX 2014006998A MX 2014006998 A MX2014006998 A MX 2014006998A MX 2014006998 A MX2014006998 A MX 2014006998A MX 2014006998 A MX2014006998 A MX 2014006998A
Authority
MX
Mexico
Prior art keywords
antibodie
present
therapeutic anti
chimeric therapeutic
applications
Prior art date
Application number
MX2014006998A
Other languages
English (en)
Other versions
MX358502B (es
Inventor
Roy H Larsen
Jostein Dahle
Original Assignee
Nordic Nanovector As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector As filed Critical Nordic Nanovector As
Publication of MX2014006998A publication Critical patent/MX2014006998A/es
Publication of MX358502B publication Critical patent/MX358502B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a anticuerpos quiméricos o humanizados derivados de un anticuerpo monoclonal HH1 de ratón. Las aplicaciones de la presente invención incluyen aplicaciones terapéuticas en las que las composiciones farmacéuticas que comprenden los anticuerpos de la presente invención o radioinmunoconjugados de estos se utilizan para tratar enfermedades malignas de los linfocitos B.
MX2014006998A 2011-12-13 2012-12-12 Anticuerpo quimerico terapeutico anti-cd37 hh1. MX358502B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161569981P 2011-12-13 2011-12-13
PCT/IB2012/057230 WO2013088363A1 (en) 2011-12-13 2012-12-12 Chimeric therapeutic anti - cd37 antibodie hh1

Publications (2)

Publication Number Publication Date
MX2014006998A true MX2014006998A (es) 2015-02-20
MX358502B MX358502B (es) 2018-08-23

Family

ID=47603883

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006998A MX358502B (es) 2011-12-13 2012-12-12 Anticuerpo quimerico terapeutico anti-cd37 hh1.

Country Status (17)

Country Link
US (2) US20140348745A1 (es)
EP (2) EP3272364B1 (es)
JP (1) JP2015501654A (es)
KR (1) KR20140103140A (es)
CN (2) CN104114192A (es)
AU (1) AU2012354140B2 (es)
BR (1) BR112014014258A2 (es)
CA (1) CA2858964A1 (es)
ES (1) ES2827787T3 (es)
HK (1) HK1203372A1 (es)
IL (1) IL233084A (es)
MX (1) MX358502B (es)
PH (1) PH12014501338A1 (es)
PL (1) PL3272364T3 (es)
RU (1) RU2658438C2 (es)
SG (1) SG11201403134PA (es)
WO (1) WO2013088363A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201501803YA (en) 2010-03-12 2015-05-28 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
EP3332813B1 (en) * 2013-06-07 2019-05-29 Nordic Nanovector ASA Combination therapy comprising anti-cd20 antibody and the radiolabeled hh1 monoclonal antibody
AU2014296219A1 (en) 2013-08-01 2016-02-25 Agensys, Inc. Antibody drug conjugates (ADC) that bind to CD37 proteins
US9433690B1 (en) 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
JP6979877B2 (ja) 2015-06-08 2021-12-15 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲートおよび抗ｃｄ２０抗体の組み合わせ
CA2995243A1 (en) 2015-08-28 2017-03-09 Debiopharm International, S.A. Antibodies and assays for detection of cd37
GB201600328D0 (en) * 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
JP2019529433A (ja) * 2016-09-16 2019-10-17 ノルディック ナノベクター アルメン アクスイェ セルスカプ リロトマブおよび１７７Ｌｕ‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法
JP2020510608A (ja) 2016-11-02 2020-04-09 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲート療法を改善するための方法
SI3568205T1 (sl) * 2017-01-12 2023-12-29 Radiomedix Inc. Zdravljenje rakastih celic, ki prekomerno izražajo receptorje za somatostatin, z uporabo derivatov okreotida, kelatiranih v radioizotope
US20210106703A1 (en) * 2017-11-22 2021-04-15 Nordic Nanovector Asa Radioimmunoconjugates in combination with other drugs as treatment against nhl
JP2021525735A (ja) 2018-05-30 2021-09-27 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７免疫コンジュゲート投薬レジメン
CN117241832A (zh) 2021-03-19 2023-12-15 海德堡医药研究有限责任公司 B淋巴细胞特异性的鹅膏毒素抗体缀合物
CN118339188A (zh) 2021-09-21 2024-07-12 齐鲁普吉湾生物治疗公司 用于制备融合蛋白和双特异性抗体的异二聚体Fc
JP2024178476A (ja) * 2021-09-29 2024-12-25 国立大学法人大阪大学 α線放出抗体薬物複合体
WO2023057595A1 (en) * 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
US20250333531A1 (en) * 2021-10-06 2025-10-30 Nordic Nanovector Asa Humanized hh1
IL312237A (en) 2021-10-18 2024-06-01 Daiichi Sankyo Co Ltd Anti-cd37 antibody-drug conjugate
WO2023133488A1 (en) * 2022-01-06 2023-07-13 The General Hospital Corporation Methods of cell ablation
WO2025083205A1 (en) 2023-10-18 2025-04-24 Debiopharm International S.A. Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US8101179B2 (en) * 2005-03-31 2012-01-24 Biomedics Inc. Anti-CD20 monoclonal antibody
HUE026303T2 (hu) * 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
TW201031749A (en) * 2009-02-10 2010-09-01 Otsuka Chemical Co Ltd IgG-Fc fragment and method for manufacturing the same
NO331080B1 (no) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
SG10201501803YA (en) * 2010-03-12 2015-05-28 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof

Also Published As

Publication number Publication date
RU2014125320A (ru) 2016-02-10
HK1203372A1 (en) 2015-10-30
ES2827787T3 (es) 2021-05-24
BR112014014258A2 (pt) 2020-10-27
KR20140103140A (ko) 2014-08-25
PL3272364T3 (pl) 2021-04-06
NZ626188A (en) 2016-12-23
EP3272364B1 (en) 2020-07-29
AU2012354140A1 (en) 2014-07-03
IL233084A0 (en) 2014-08-03
WO2013088363A1 (en) 2013-06-20
EP3272364A1 (en) 2018-01-24
EP2790740A1 (en) 2014-10-22
AU2012354140B2 (en) 2017-10-12
MX358502B (es) 2018-08-23
RU2658438C2 (ru) 2018-06-21
CN104114192A (zh) 2014-10-22
SG11201403134PA (en) 2014-07-30
IL233084A (en) 2017-06-29
CA2858964A1 (en) 2013-06-20
CN109276713A (zh) 2019-01-29
US20140348745A1 (en) 2014-11-27
JP2015501654A (ja) 2015-01-19
PH12014501338A1 (en) 2014-09-15
US20180194852A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
PH12014501338A1 (en) Chimeric therapeutic anti-cd37 antibodie hh1
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
IN2014KN00848A (es)
SG194701A1 (en) Anti-cd40 antibodies and methods of use
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
TN2012000462A1 (en) Anti-cd40 antibodies
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
NZ707086A (en) Anti-cd40 antibodies and methods of use
PH12014502406A1 (en) Anti-il-23p19 antibodies
MX2013009362A (es) Anticuerpo contra el csf-1r.
PH12017500864A1 (en) Anti-notch1 antibodies
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
TN2014000107A1 (en) Anti-aplhabetatcr antibody
MX369148B (es) Agentes de unión kir3dl2.
MY173377A (en) Anti-b7-h3 antibody
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
PL2550296T3 (pl) Przeciwciała monoklonalne w leczeniu nowotworów
PH12015501360A1 (en) Bmp-6 antibodies
BR112013003257A2 (pt) anticorpos egfr humanizados.
WO2012026878A8 (en) Monoclonal antibody specific to major neutralizing epitope of influenza h5 hemagglutinin
MX2013011629A (es) Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
TN2013000265A1 (en) Anti-cd38 antibodies

Legal Events

Date Code Title Description
FG Grant or registration